

# CITATION REPORT

List of articles citing

A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects

DOI: 10.1007/s00280-017-3286-9

Cancer Chemotherapy and Pharmacology, 2017, 79, 881-888.

**Source:** <https://exaly.com/paper-pdf/66607896/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
33	The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , <b>2018</b> , 18, 95-113	3	32
32	ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer. <i>Expert Opinion on Biological Therapy</i> , <b>2018</b> , 18, 335-341	5.4	4
31	Distribution of therapeutic proteins into thoracic lymph after intravenous administration is protein size-dependent and primarily occurs within the liver and mesentery. <i>Journal of Controlled Release</i> , <b>2018</b> , 272, 17-28	11.7	11
30	Efficacy and safety of the trastuzumab biosimilar candidate CT-P6. <i>Future Oncology</i> , <b>2018</b> , 14, 1909-1919	3.6	8
29	A Randomized Phase I Study Comparing the Pharmacokinetics of HD201, a Trastuzumab Biosimilar, With European Union-sourced Herceptin. <i>Clinical Therapeutics</i> , <b>2018</b> , 40, 396-405.e4	3.5	13
28	ABP 980: A Trastuzumab Biosimilar. <i>BioDrugs</i> , <b>2018</b> , 32, 511-514	7.9	2
27	Milestones over the development of SB3, a trastuzumab biosimilar. <i>Future Oncology</i> , <b>2018</b> , 14, 2795-2803	3.6	0
26	Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 987-998	21.7	48
25	Biosimilars in oncology: A decade of experience with granulocyte colony-stimulating factor and its implications for monoclonal antibodies. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 102785	7	2
24	Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice. <i>American Journal of Health-System Pharmacy</i> , <b>2019</b> , 76, 1725-1738	2.2	9
23	Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. <i>Targeted Oncology</i> , <b>2019</b> , 14, 647-656	5	6
22	Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab. <i>Pharmaceutical Research</i> , <b>2019</b> , 36, 177	4.5	8
21	Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?. <i>BioDrugs</i> , <b>2019</b> , 33, 437-446	7.9	8
20	Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab. <i>BioDrugs</i> , <b>2019</b> , 33, 321-333	7.9	16
19	Biosimilars for breast cancer: a review of HER2-targeted antibodies in the United States. <i>Therapeutic Advances in Medical Oncology</i> , <b>2019</b> , 11, 1758835919887044	5.4	13
18	[Biosimilars antibodies: positioning compared to originators - the experience in rheumatology and the biosimilars of trastuzumab in oncology]. <i>Medecine/Sciences</i> , <b>2019</b> , 35, 1137-1145		
17	Pivotal Considerations for Optimal Deployment of Healthy Volunteers in Oncology Drug Development. <i>Clinical and Translational Science</i> , <b>2020</b> , 13, 31-40	4.9	3

16	A randomized Phase I pharmacokinetic trial comparing the potential biosimilar trastuzumab (SIBP-01) with the reference product (Herceptin®) in healthy Chinese male volunteers. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2020</b> , 16, 997-1003	5.5	2
15	A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults. <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 755-762	5.9	4
14	Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1070-1080	2.2	9
13	A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2021</b> , 87, 349-359	3.5	4
12	A Clinical Review of Biosimilars Approved in Oncology. <i>Annals of Pharmacotherapy</i> , <b>2021</b> , 55, 362-377	2.9	1
11	Safety and pharmacokinetics of a new biosimilar trastuzumab (HL02): a Phase I bioequivalence study in healthy Chinese men. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 1-8	5.4	2
10	Progress in oncology biosimilars till 2020: Scrutinizing comparative studies of biosimilar monoclonal antibodies. <i>Journal of Oncology Pharmacy Practice</i> , <b>2021</b> , 27, 1195-1204	1.7	1
9	TROIKA-1: A double-blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU-Herceptin and US-Herceptin in healthy male subjects. <i>Pharmacology Research and Perspectives</i> , <b>2021</b> , 9, e00683	3.1	0
8	Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations. <i>Oncology and Therapy</i> , <b>2021</b> , 9, 225-238	2.7	0
7	Phase 3 LILAC study sets standard for clinical evaluation of oncology biosimilars. <i>Oncotarget</i> , <b>2019</b> , 10, 8-9	3.3	2
6	A pharmacokinetic study to comparatively evaluate the bioequivalence and safety of a humanized recombinant monoclonal antibody targeting human epidermal growth factor receptor-2 with the reference Herceptin in healthy Chinese subjects.. <i>Investigational New Drugs</i> , <b>2022</b> , 1	4.3	
5	Biosimilar Monoclonal Antibodies in Latin America.		
4	Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer. <b>2022</b> , 10, 2045		0
3	A Randomized, Single-dose, Phase I Clinical Comparison of a Trastuzumab Biosimilar With a Reference Trastuzumab Formulation in Healthy Chinese Male Volunteers.		0
2	Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer In Analysis of a Large University Breast Cancer Centre.		0
1	Comparing the pharmacokinetics, safety, and immunogenicity of HLX02 to US- and EU-approved trastuzumab in healthy Chinese male subjects: A Phase I, randomized, double-blind, parallel-group study. 1-9		0